Abstract
Expression of carboxylesterase 2 in colorectal tumor tissues and serum carboxylesterase 2 levels at different stages of the disease were investigated by Western blotting. Carboxylesterase 2 was decreasing in tumor tissues from TNM stages 0 through IV (n = 20); the expression of carboxylesterase 2 was similar between "normal" and tumor tissues (n = 20); serum carboxylesterase 2 levels were similar among patients at different stages of the disease. These results indicate that local expression of carboxylesterase 2 is downregulated following progression of the disease; carboxylesterase 2 expression is altered in histology "normal" tissues from stages I through IV before histopathological changes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / enzymology*
-
Adenocarcinoma / pathology
-
Animals
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Biomarkers, Tumor / metabolism*
-
Blotting, Western
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Carboxylesterase / metabolism*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / enzymology*
-
Colorectal Neoplasms / pathology
-
Disease Progression
-
Down-Regulation
-
Humans
-
Immunoglobulin G / immunology
-
Irinotecan
-
Mice
-
Neoplasm Staging
-
Topoisomerase I Inhibitors
Substances
-
Antineoplastic Agents, Phytogenic
-
Biomarkers, Tumor
-
Immunoglobulin G
-
Topoisomerase I Inhibitors
-
Irinotecan
-
CES2 protein, human
-
Carboxylesterase
-
Camptothecin